SCHEMBL25814848

SCHEMBL25814848

Cc1c(Br)cc(C(=O)c2c(C(O)CO)oc3ccccc23)cc1Br

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EYA3 Q99504 9/20 0.62
▸ CYP2C19 P33261 9/20 0.54
▸ NR1H4 Q96RI1 4/20 0.54
▸ TTR P02766 4/20 0.54
▸ SLC22A12 Q96S37 4/20 0.54
▸ CYP2C9 P11712 3/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ ABCB11 O95342 2/20 0.54
▸ LMNA P02545 2/20 0.54
▸ PGR P06401 2/20 0.54
▸ ADRA2A P08913 2/20 0.54
▸ TBXA2R P21731 2/20 0.54
▸ OPRM1 P35372 2/20 0.54
▸ SLC6A3 Q01959 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ EYA2 O00167 1/20 0.54
▸ ABCC4 O15439 1/20 0.54
▸ PLIN1 O60240 1/20 0.54
▸ NR1I2 O75469 1/20 0.54
▸ USP2 O75604 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25814853 0.87 SLC22A12 (0.58) EYA3CYP2C19NR1H4TTRSLC22A12
SCHEMBL25814802 0.86 EYA3 (0.81) EYA3CYP2C19NR1H4TTRSLC22A12
SCHEMBL25814856 0.83 SLC22A12 (0.48) EYA3CYP2C19NR1H4TTRSLC22A12
SCHEMBL25814859 0.82 EYA3 (0.44) EYA3CYP2C19NR1H4TTRSLC22A12
SCHEMBL18058593 0.80 CYP2C19 (0.81) EYA3CYP2C19NR1H4TTRSLC22A12
SCHEMBL25814830 0.78 TTR (0.64) EYA3CYP2C19NR1H4TTRSLC22A12
Poztinurad SCHEMBL29569243 0.77 EYA3 (1.00) EYA3CYP2C19NR1H4TTRSLC22A12
Poztinurad SCHEMBL15698085 0.77 EYA3 (1.00) EYA3CYP2C19NR1H4TTRSLC22A12
SCHEMBL15698033 0.75 EYA3 (0.83) EYA3CYP2C19NR1H4TTRSLC22A12
SCHEMBL25892406 0.74 EYA3 (0.81) EYA3CYP2C19NR1H4TTRSLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218563-A1 METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE ARTHROSI THERAPEUTICS, INC. 2023-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218563-A1 METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE ATP6V1B1, REN, CYP27B1 EYA3 3141/4885CYP2C19 826/4885NR1H4 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback